S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet

USANA Health Sciences (USNA) Competitors

$48.32
+0.06 (+0.12%)
(As of 03/1/2024 ET)

USNA vs. CRON, CGC, QTRX, PRME, FUSN, ZYME, ABVX, AVNS, LQDA, and TMCI

Should you be buying USANA Health Sciences stock or one of its competitors? The main competitors of USANA Health Sciences include Cronos Group (CRON), Canopy Growth (CGC), Quanterix (QTRX), Prime Medicine (PRME), Fusion Pharmaceuticals (FUSN), Zymeworks (ZYME), ABIVAX Société Anonyme (ABVX), Avanos Medical (AVNS), Liquidia (LQDA), and Treace Medical Concepts (TMCI). These companies are all part of the "medical" sector.

USANA Health Sciences vs.

USANA Health Sciences (NYSE:USNA) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, community ranking, earnings, analyst recommendations and valuation.

USANA Health Sciences presently has a consensus price target of $48.00, suggesting a potential downside of 0.66%. Cronos Group has a consensus price target of $2.67, suggesting a potential upside of 32.01%. Given Cronos Group's higher probable upside, analysts clearly believe Cronos Group is more favorable than USANA Health Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
USANA Health Sciences
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Cronos Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Cronos Group received 69 more outperform votes than USANA Health Sciences when rated by MarketBeat users. Likewise, 61.29% of users gave Cronos Group an outperform vote while only 60.77% of users gave USANA Health Sciences an outperform vote.

CompanyUnderperformOutperform
USANA Health SciencesOutperform Votes
395
60.77%
Underperform Votes
255
39.23%
Cronos GroupOutperform Votes
464
61.29%
Underperform Votes
293
38.71%

In the previous week, Cronos Group had 6 more articles in the media than USANA Health Sciences. MarketBeat recorded 7 mentions for Cronos Group and 1 mentions for USANA Health Sciences. Cronos Group's average media sentiment score of 0.26 beat USANA Health Sciences' score of -0.50 indicating that Cronos Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
USANA Health Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative
Cronos Group
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

USANA Health Sciences has a net margin of 6.93% compared to Cronos Group's net margin of -84.15%. USANA Health Sciences' return on equity of 13.49% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
USANA Health Sciences6.93% 13.49% 10.45%
Cronos Group -84.15%-3.96%-3.85%

USANA Health Sciences has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$921.01M1.01$63.79M$3.3014.64
Cronos Group$87.24M8.83-$168.73M-$0.19-10.63

52.6% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 8.6% of Cronos Group shares are owned by institutional investors. 0.3% of USANA Health Sciences shares are owned by insiders. Comparatively, 2.0% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

USANA Health Sciences has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Summary

USANA Health Sciences and Cronos Group tied by winning 9 of the 18 factors compared between the two stocks.


Get USANA Health Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for USNA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding USNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

USNA vs. The Competition

MetricUSANA Health SciencesMedicinals & botanicals IndustryMedical SectorNYSE Exchange
Market Cap$929.73M$1.24B$5.11B$17.63B
Dividend YieldN/A4.45%2.82%3.55%
P/E Ratio14.644.08192.1522.63
Price / Sales1.0115.493,058.686.78
Price / Cash10.98245.69100.8118.47
Price / Book1.872.394.535.86
Net Income$63.79M-$177.55M$115.01M$863.03M
7 Day Performance-0.92%-2.09%5.72%1.63%
1 Month Performance2.31%-3.42%12.82%3.14%
1 Year Performance-23.88%-14.23%12.95%94.49%

USANA Health Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRON
Cronos Group
3.2637 of 5 stars
$2.30
+2.7%
$2.75
+19.6%
-2.9%$876.99M$90.51M-8.21447Earnings Report
News Coverage
CGC
Canopy Growth
1.9082 of 5 stars
$3.53
+1.7%
$4.87
+37.9%
-85.7%$321.64M$362.24M-0.231,621Short Interest ↑
QTRX
Quanterix
1.7178 of 5 stars
$24.17
-3.7%
$31.60
+30.7%
+145.2%$914.35M$105.52M-23.47370Earnings Report
News Coverage
Gap Down
PRME
Prime Medicine
2.3559 of 5 stars
$9.39
+8.4%
$18.14
+93.2%
N/A$913.84MN/A-4.65175News Coverage
Gap Up
FUSN
Fusion Pharmaceuticals
1.609 of 5 stars
$12.50
-1.2%
$13.80
+10.4%
+155.7%$905.13M$1.46M-7.67101Short Interest ↑
ZYME
Zymeworks
0.6945 of 5 stars
$12.90
+4.3%
$13.67
+5.9%
+56.4%$903M$412.48M4.15252Upcoming Earnings
ABVX
ABIVAX Société Anonyme
2.3215 of 5 stars
$14.98
+1.6%
$17.50
+16.8%
N/A$942.69MN/A0.0026Short Interest ↑
Gap Up
AVNS
Avanos Medical
3.0456 of 5 stars
$19.36
+0.5%
$31.00
+60.2%
-34.5%$894.26M$673.30M-14.663,771
LQDA
Liquidia
2.8432 of 5 stars
$14.69
+0.5%
$18.33
+24.8%
+102.2%$953.45M$18.32M-16.8863Positive News
TMCI
Treace Medical Concepts
2.5023 of 5 stars
$14.38
+0.3%
$19.58
+36.2%
-34.4%$886.96M$141.84M-18.20423Earnings Report
News Coverage

Related Companies and Tools

This page (NYSE:USNA) was last updated on 3/3/2024 by MarketBeat.com Staff